{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:56:04Z","timestamp":1791831364671,"version":"4.3.4"},"reference-count":141,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.pharmthera.2013.08.005","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T13:15:46Z","timestamp":1377782146000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Mechanisms of aspirin resistance"],"prefix":"10.1016","volume":"141","author":[{"given":"Christopher N.","family":"Floyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.08.005_bb0005","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","volume":"56","author":"Abraham","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/FJC.0b013e3181af6d9c","article-title":"Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study","volume":"54","author":"Adamopoulos","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejim.2006.12.004","article-title":"Aspirin esterase activity - Evidence for skewed distribution in healthy volunteers","volume":"18","author":"Adebayo","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.STR.0000056527.34434.59","article-title":"Dipyridamole enhances NO\/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo\/ex vivo studies","volume":"34","author":"Aktas","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0002-9149(99)00049-1","article-title":"Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb\/IIIa in Unstable angina: receptor suppression using integrilin therapy","volume":"83","author":"Alexander","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0030","first-page":"217","article-title":"Evaluation of the pharmacodynamics of acetylsalicylic acid 81mg with or without esomeprazole 20mg in healthy volunteers","volume":"12","author":"Andersson","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000285167","article-title":"Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans","volume":"85","author":"Anger","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0045","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1111\/j.1538-7836.2008.03133.x","article-title":"Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2","volume":"6","author":"Armstrong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.CIR.102.8.840","article-title":"Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis","volume":"102","author":"Belton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0065","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd985","article-title":"Scientific and therapeutic advances in antiplatelet therapy","volume":"2","author":"Bhatt","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0070","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.freeradbiomed.2004.10.021","article-title":"Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects","volume":"38","author":"Bonaterra","year":"2005","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0016-5085(19)32262-0","article-title":"Aspirin esterase of gastric mucosal origin","volume":"73","author":"Builder","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0049-3848(87)90103-4","article-title":"Paired analysis of urinary thromboxane B2 metabolites in humans","volume":"47","author":"Catella","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/gtmb.2010.0225","article-title":"The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients","volume":"15","author":"Chakroun","year":"2011","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0105","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1160\/TH08-03-0172","article-title":"The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid","volume":"100","author":"Clappers","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0110","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0115","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0120","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780250509","article-title":"Aspirin survival in human blood modulated by the concentration of erythrocytes","volume":"25","author":"Costello","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0125","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0016-5085(99)70545-7","article-title":"Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans","volume":"117","author":"Cryer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00062752-199704050-00006","article-title":"Platelet kinetics","volume":"4","author":"Dale","year":"1997","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3181\/00379727-163-40716","article-title":"The effects of aspirin on megakaryocyte prostaglandin production","volume":"163","author":"Demers","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01662127","article-title":"Pharmakologisches uber Aspirin (Acetylsalicylsaure)","author":"Dreser","year":"1899","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0160","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0155","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/01.RES.0000214553.37930.3e","article-title":"De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin","volume":"98","author":"Evangelista","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/newbio231237a0","article-title":"Indomethacin and aspirin abolish prostaglandin release from the spleen","volume":"231","author":"Ferreira","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1592\/phco.25.4.503.61021","article-title":"Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction","volume":"25","author":"Fischer","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0185","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/0002-9149(91)90379-Y","article-title":"Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists","volume":"68","author":"FitzGerald","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0190","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0195","first-page":"4441","article-title":"Aspirin enhances multidrug resistance gene 1 expression in human Molt-4T lymphoma cells","volume":"20","author":"Flescher","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0200","article-title":"The platelet fibrinogen receptor: from megakaryocyte to the mortuary","volume":"1","author":"Floyd","year":"2012","journal-title":"J R Soc Med Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0205","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11630740-000000000-00000","article-title":"Comparative pharmacokinetics and pharmacodynamics of platelet ADP receptor antagonists and their clinical implications","volume":"51","author":"Floyd","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garcia Rodriguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0215","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1161\/01.CIR.0000132491.96623.04","article-title":"Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population","volume":"109","author":"Garcia Rodriguez","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0220","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2036.1997.00216.x","article-title":"Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats","volume":"11","author":"Giraud","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","article-title":"Pharmacogenetics of aspirin resistance: a comprehensive systematic review","volume":"66","author":"Goodman","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0230","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbagen.2005.11.018","article-title":"Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases","volume":"1760","author":"Gresner","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0240","article-title":"Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin","author":"Grosser","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1538-7836.2010.04115.x","article-title":"Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease","volume":"9","author":"Grove","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0250","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0255","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0260","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jps.2600580114","article-title":"Influence of the route of administration on the area under the plasma concentration-time curve","volume":"58","author":"Harris","year":"1969","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0037-1616935","article-title":"Assessment of platelet function in the laboratory","volume":"29","author":"Harrison","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2036.2009.04133.x","article-title":"Predictors of gastroduodenal erosions in patients taking low-dose aspirin","volume":"31","author":"Hart","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0280","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0285","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/01.CIR.0000142056.69970.DB","article-title":"Terms and conditions: semantic complexity and aspirin resistance","volume":"110","author":"Hennekens","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0290","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1073\/pnas.89.16.7384","article-title":"Human cyclooxygenase-2 cDNA","volume":"89","author":"Hla","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0295","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0300","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.3390\/molecules17055615","article-title":"Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review","volume":"17","author":"Hofer","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1160\/TH12-07-0532","article-title":"High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs \u2014 pharmacological mechanisms and clinical relevance","volume":"109","author":"Hohlfeld","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0310","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/026765919801300603","article-title":"Platelets and cardiopulmonary bypass","volume":"13","author":"Hyde","year":"1998","journal-title":"Perfusion"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0315","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/003655200750024083","article-title":"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man","volume":"35","author":"Inarrea","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0320","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","author":"ISIS-2 Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0325","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2003-12-4330","article-title":"The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage","volume":"104","author":"Jedlitschky","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.pharmthera.2013.08.005_bb0330","doi-asserted-by":"crossref","first-page":"976.e7","DOI":"10.1016\/j.ahj.2006.02.017","article-title":"Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers","volume":"151","author":"Karha","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0335","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2003.09.041","article-title":"Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor","volume":"43","author":"Kearney","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0345","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7150\/ijms.7.90","article-title":"Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data","volume":"7","author":"Kotani","year":"2010","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0340","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1758-5996-2-50","article-title":"Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus","volume":"2","author":"Kotani","year":"2010","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0350","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0355","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0360","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","article-title":"A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease","volume":"28","author":"Lordkipanidze","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0365","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1742-7843.2006.pto_371.x","article-title":"Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?","volume":"98","author":"MacDonald","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0375","first-page":"321","article-title":"Cell\u2013cell interactions between platelets, macrophages, eosinophils and natural killer cells in thromboxane A2 biosynthesis","volume":"6","author":"Maghni","year":"1993","journal-title":"J Lipid Mediat"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0380","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1172\/JCI109967","article-title":"Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells","volume":"66","author":"Marcus","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0385","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2011.03.049","article-title":"Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting","volume":"58","author":"Mattiello","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0390","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/CIRCULATIONAHA.105.542696","article-title":"Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers","volume":"112","author":"McAdam","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0395","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0400","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","article-title":"Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase","volume":"90","author":"Mitchell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/bdd.2510070104","article-title":"Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets","volume":"7","author":"Montgomery","year":"1986","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0415","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2165\/00003088-198510020-00004","article-title":"Clinical pharmacokinetics of the salicylates","volume":"10","author":"Needs","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0420","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ajg.2011.385","article-title":"Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction","volume":"107","author":"Ng","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0425","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5414\/CPP47564","article-title":"Evaluation of the pharmacokinetic interaction between esomeprazole (40mg) and acetylsalicylic acid (325mg) in healthy volunteers","volume":"47","author":"Niazi","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.CIR.76.1.6","article-title":"Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes","volume":"76","author":"Nowak","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0435","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01037940","article-title":"Effect of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation in man","volume":"25","author":"Nuotto","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2013.08.005_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000200098","article-title":"Omeprazole: pharmacology, pharmacokinetics and interactions","volume":"44","author":"Oosterhuis","year":"1989","journal-title":"Digestion"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0445","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0005-2760(94)90055-8","article-title":"Thromboxane A2 synthase activity in platelet free human monocytes","volume":"1215","author":"Orlandi","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0450","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0929-7855(95)00015-I","article-title":"Prostaglandin endoperoxide synthases-1 and -2","volume":"12","author":"Otto","year":"1995","journal-title":"J Lipid Mediat Cell Signal"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0455","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0049-3848(86)90218-5","article-title":"Production of eicosanoids by deendothelialized rabbit aorta: interaction between platelets and vascular wall in the synthesis of prostacyclin","volume":"42","author":"Papp","year":"1986","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0460","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0465","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/archinte.164.8.852","article-title":"Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction","volume":"164","author":"Patel","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0470","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0480","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI112341","article-title":"Estimated rate of thromboxane secretion into the circulation of normal humans","volume":"77","author":"Patrono","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0475","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0485","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0490","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.165.3.1605","article-title":"Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors","volume":"165","author":"Penglis","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0495","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1160\/TH08-11-0753","article-title":"Cyclooxygenase-1 haplotype C50T\/A-842G does not affect platelet response to aspirin","volume":"101","author":"Pettinella","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0505","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","article-title":"Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients","volume":"43","author":"Pulcinelli","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0500","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1538-7836.2006.01755.x","article-title":"More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm","volume":"4","author":"Pulcinelli","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0510","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1073\/pnas.1033060100","article-title":"The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs","volume":"100","author":"Reid","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0515","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/blood-2005-06-2206","article-title":"Mechanisms of organelle transport and capture along proplatelets during platelet production","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0520","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2007.12.011","article-title":"Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production","volume":"122","author":"Riondino","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0525","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0530","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0535","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0540","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jps.2600610312","article-title":"Absorption kinetics of aspirin in man following oral administration of an aqueous solution","volume":"61","author":"Rowland","year":"1972","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0545","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2008.07.063","article-title":"Impact of \u201cnuisance\u201d bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation","volume":"102","author":"Roy","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0550","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules","volume":"29","author":"Russel","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0555","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1067\/mhj.2001.113994","article-title":"Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin","volume":"141","author":"Santopinto","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0560","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/hrt.2010.217547","article-title":"Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)","volume":"97","author":"Scheiman","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0565","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11239-006-8670-y","article-title":"Possible mechanisms of drug-induced aspirin and clopidogrel resistance","volume":"22","author":"Schroeder","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0570","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/12487","article-title":"MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs","volume":"5","author":"Schuetz","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0575","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction","volume":"95","author":"Schwartz","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0580","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0585","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1479-5876-6-47","article-title":"\u2018Aspirin resistance\u2019 or treatment non-compliance: which is to blame for cardiovascular complications?","volume":"6","author":"Shantsila","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0590","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0595","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V81.3.835.bloodjournal813835","article-title":"Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis","volume":"81","author":"Simsek","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0600","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ageing\/19.2.128","article-title":"The kinetics of plasma aspirin esterase in relation to old age and frailty","volume":"19","author":"Summerbell","year":"1990","journal-title":"Age Ageing"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0610","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0615","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0620","series-title":"UniProtKB Protein Knowledgebase","article-title":"Prostaglandin G\/H synthase 1","author":"UniProt Consortium","year":"2012"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0625","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0609.1993.tb00160.x","article-title":"Influence of aspirin on human megakaryocyte prostaglandin synthesis","volume":"50","author":"van Pampus","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0630","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0635","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0640","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1160\/TH05-04-0889","article-title":"Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction","volume":"94","author":"von Pape","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0645","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09537100120104890","article-title":"Towards a definition of aspirin resistance: a typological approach","volume":"13","author":"Weber","year":"2002","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0650","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJM199604253341703","article-title":"A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis","volume":"334","author":"Weiss","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0655","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2006-08-042192","article-title":"mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets","volume":"109","author":"Weyrich","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0660","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-198510050-00002","article-title":"Clinical significance of esterases in man","volume":"10","author":"Williams","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0665","first-page":"9","article-title":"The changing face of acute coronary syndromes","volume":"50","author":"Williams","year":"2011","journal-title":"Heart Metab"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0670","first-page":"505","article-title":"Who are the frail elderly?","volume":"68","author":"Woodhouse","year":"1988","journal-title":"Q J Med"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0675","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI112995","article-title":"Interaction between lymphocytes and platelets in the synthesis of prostacyclin","volume":"79","author":"Wu","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0680","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"Wurtz","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0685","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/20.1.16","article-title":"The association of age with aspirin esterase activity in human liver","volume":"20","author":"Yelland","year":"1991","journal-title":"Age Ageing"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0690","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2013.08.005_bb0695","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5551\/jat.14092","article-title":"Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C","volume":"20","author":"Yi","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0700","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2013.08.005_bb0705","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0952-3278(97)90502-0","article-title":"Cell\u2013cell interaction between platelets and IL-1 beta-stimulated vascular smooth muscle cells in synthesis of thromboxane A2","volume":"56","author":"Zou","year":"1997","journal-title":"Prostaglandins Leukot Essent Fatty Acids"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T16:17:35Z","timestamp":1596385055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0163725813001812"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.08.005","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of aspirin resistance","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}